Literature DB >> 28215917

Onchocerciasis in the Democratic Republic of Congo: Survey of knowledge, attitude and perception in Bandundu province.

Jean-Claude Makenga Bof1, Dieudonne Mpunga2, Emery N Soa2, Fortunat Ntumba3, Didier Bakajika3, Michele E Murdoch4, Yves Coppieters5.   

Abstract

A community-directed treatment with ivermectin (CDTI) for fighting onchocerciasis was started in 2003 in the hyperendemic province of Bandundu, Democratic Republic of Congo (DRC); such initiative was supported by the African Programme for Onchocerciasis Control (APOC). As the APOC stopped at the end of 2015, there was an urgent need to assess the sustainability of an ivermectin treatment. A cross-sectional survey of knowledge, attitude and perception was conducted to determine the awareness level of local population regarding the disease. A multi-stage random sampling technique allowed the selection of 450 heads of households. Most respondents (96.9%) knew about onchocerciasis as a disease. The black-fly was viewed as the causing agent of onchocerciasis by 49.9% of respondents. The most commonly cited clinical manifestations were nodules (34.4%) and pruritus (31.1%), while blindness was the most frequently reported complication (90.7%). Approximately 55.1% of respondents had a good knowledge of onchocerciasis and CDTI. Overall, only 37% of participants had a favourable attitude and 46% a positive perception. Good knowledge was associated with school attendance (adjusted OR=1.9, 95%CI: 1.3-2.8, p=0.001), while education and continuation of treatment were related with good attitude (adjusted OR=9.7, 95%CI:4.8-19.5 and adjusted OR=19.8, 95%CI: 9.7-40.6, respectively, both with p<0.001). Good perception was associated with being at least 46 years old, non-Catholic and continuing the treatment (adjusted OR=3.2, 95%CI:1.2-9.1; adjusted OR=29.6, 95%CI:14.1-62.2 and adjusted OR=5.1, 95%CI:1.6-16.0 respectively, all with p<0.001). A good level of knowledge, attitude and perception is needed for a massive adherence of population to onchocerciasis control programmes. In the area of study (Moanza, DRC), good attitude and perception motivated the continuation of treatment in the population. In the future, different plans should focus on educational strategies to maintain a massive adherence and reduce onchocerciasis prevalence.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Attitude; DRC; Ivermectin; Kinshasa; Knowledge; Mont-Ngafula; Onchocerciasis; Perception

Mesh:

Substances:

Year:  2017        PMID: 28215917     DOI: 10.1016/j.jiph.2017.01.017

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  5 in total

Review 1.  Review of the National Program for Onchocerciasis Control in the Democratic Republic of the Congo.

Authors:  Jean-Claude Makenga Bof; Fortunat Ntumba Tshitoka; Daniel Muteba; Paul Mansiangi; Yves Coppieters
Journal:  Trop Med Infect Dis       Date:  2019-06-13

2.  Community Participation in and Perception of Community-Directed Treatment with Ivermectin in Kinshasa, DRC.

Authors:  Jean-Claude Makenga Bof; Paul Mansiangi; Horlyne Nsangi; Éric Mafuta; Isabelle Aujoulat; Yves Coppieters
Journal:  Trop Med Infect Dis       Date:  2019-07-19

3.  Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo.

Authors:  Jean-Claude Makenga Bof; Daniel Muteba; Paul Mansiangi; Félicien Ilunga-Ilunga; Yves Coppieters
Journal:  BMC Pharmacol Toxicol       Date:  2019-08-16       Impact factor: 2.483

Review 4.  Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.

Authors:  Gebremedhin Gebrezgabiher; Zeleke Mekonnen; Delenasaw Yewhalaw; Asrat Hailu
Journal:  Infect Dis Poverty       Date:  2019-07-04       Impact factor: 10.485

5.  Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon.

Authors:  Armelle Forrer; Samuel Wanji; Elisabeth Dibando Obie; Theobald Mue Nji; Louise Hamill; Kim Ozano; Helen Piotrowski; Laura Dean; Abdel J Njouendou; Relindis Ekanya; Winston Patrick Chounna Ndongmo; Ebua Gallus Fung; Dum-Buo Nnamdi; Raphael A Abong; Amuam Andrew Beng; Mathias Esum Eyong; Bertrand L Ndzeshang; Desmond Akumtoh Nkimbeng; Samuel Teghen; Anicetus Suireng; Ernerstine Ebot Ashu; Emmanuel Kah; Michele M Murdoch; Rachael Thomson; Sally Theobald; Peter Enyong; Joseph D Turner; Mark J Taylor
Journal:  BMJ Glob Health       Date:  2021-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.